The company has elegant environment, scientific management, advanced equipment, solid preparation, raw materials and other production lines, and successfully passed GMP certification. At present, there are more than 20 kinds of Chinese and western medicines and raw materials on the market. The main products are Xinnaojian tablets (capsules), Sanqi capsules, sucralfate tablets, vitamin D3 raw materials and lansoprazole raw materials.
Faced with the impact of the international financial crisis, the company relies on a good management foundation and business philosophy to seek development in the crisis. The company also invested 40 million yuan to build a new production line for small-volume injections and freeze-dried powder injections, which is expected to pass GMP certification and put into use in 20 10. It will form an annual production capacity of 65.438 billion tablets, 500 million capsules, 65.438 billion liniment bags, 5T raw materials (VD3), 5t raw materials (lansoprazole), 65.438 million freeze-dried injections and 50 million small-capacity water injections.